Accepted Manuscript

Pseudoprogression associated with clinical deterioration and worsening quality of life in malignant pleural mesothelioma

M.B. Barnet, R. Zielinski, A. Warby, C.R. Lewis, S. Kao

PII: S1556-0864(17)30735-9

DOI: 10.1016/j.jtho.2017.09.001

Reference: JTHO 693

To appear in: Journal of Thoracic Oncology

Received Date: 20 August 2017

Revised Date: 1 September 2017 Accepted Date: 2 September 2017

Please cite this article as: Barnet M, Zielinski R, Warby A, Lewis C, Kao S, Pseudoprogression associated with clinical deterioration and worsening quality of life in malignant pleural mesothelioma, *Journal of Thoracic Oncology* (2017), doi: 10.1016/j.jtho.2017.09.001.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

Pseudoprogression associated with clinical deterioration and worsening quality of life in malignant pleural mesothelioma

MB. Barnet^{1,2}, R. Zielinski^{3,4}, A. Warby⁵, CR Lewis^{2,6}, S. Kao^{5,7}

Corresponding author: Dr. Megan B. Barnet

Garvan Institute of Medical Research, 384 Victoria St, Darlinghurst, NSW 2010 m.barnet@garvan.org.au / Ph: +61 410 323 403 / F: +61 9383 1000

Disclosure Statement:

A Warby, CR Lewis: No conflicts of interest to disclose.

M. Barnet: Dr. Barnet reports non-financial support from BMS, outside the submitted work.

R. Zielinski: Dr. Zielinski sits on an advisory board for MSD, outside the submitted work.

S. Kao: Dr. Kao reports non-financial support from BMS, non-financial support from Boeringer, personal fees and non-financial support from Roche, personal fees from Pfizer, personal fees and non-financial support from AstraZeneca, outside the submitted work.

¹ Garvan Institute of Medical Research

² University of NSW

³ Western Sydney University

⁴ Central West Cancer Care Centre

⁵ University of Sydney

⁶ Prince of Wales Hospital

⁷ Chris O'Brien Lifehouse

Download English Version:

https://daneshyari.com/en/article/8787884

Download Persian Version:

https://daneshyari.com/article/8787884

<u>Daneshyari.com</u>